Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.

Smith MR, Klotz L, van der Meulen E, Colli E, Tankó LB

The Journal of urology25 Sept 2011Cited by 43 (Europe PMC)

PMID21944083PMCIDPMC3712275DOI10.1016/j.juro.2011.07.035PepBankPUB-21944083

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studySafety outcome
In men with prostate cancer, first cardiovascular disease events were reported in 92 men in the year before study entry and in 168 after degarelix treatment.
In plain wordsIn men with prostate cancer, first cardiovascular events were reported in 92 men in the year before study entry and 168 after degarelix.
Peptide
Degarelix
Outcome
Direction not reportedFirst cardiovascular disease events
Study
n = 1,704
Comparator
year before study entry
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Measurements
First cardiovascular disease events
92 men
year before study entry
First cardiovascular disease events
168 men
after degarelix treatment
Source sentences
Summary
First time cardiovascular disease events were reported in 92 men in the year before study entry and in 168 after degarelix treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408301
02HumanObservational studySafety outcome
In men with prostate cancer, cardiovascular event rates were similar before and after degarelix treatment.
In plain wordsIn men with prostate cancer, cardiovascular event rates were similar before and after degarelix treatment.
Peptide
Degarelix
Outcome
No significant changeCardiovascular event rate in total population
Study
n = 1,704
Comparator
before treatment
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Measurements
Before treatment rate
5.5 /100 person-years
total population
After treatment rate
6.1 /100 person-years
total population
Source sentences
Summary
Event rates were similar before and after degarelix treatment in the total population (5.5 vs 6.1/100 person-years, p = 0.45) and in men without cardiovascular disease (5.6 vs 4.3/100 person-years, p = 0.11).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408302
03HumanObservational studySafety outcome
In men without cardiovascular disease, event rates were similar before and after degarelix treatment.
In plain wordsIn men without cardiovascular disease, event rates were similar before and after degarelix treatment.
Peptide
Degarelix
Outcome
No significant changeCardiovascular event rate without baseline cardiovascular disease
Study
n: not reported in source
Comparator
before treatment
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Measurements
Before treatment rate
5.6 /100 person-years
without cardiovascular disease
After treatment rate
4.3 /100 person-years
without cardiovascular disease
Source sentences
Summary
Event rates were similar before and after degarelix treatment in the total population (5.5 vs 6.1/100 person-years, p = 0.45) and in men without cardiovascular disease (5.6 vs 4.3/100 person-years, p = 0.11).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408303
04HumanObservational studySafety outcome
In men with baseline cardiovascular disease, event rates appeared higher after degarelix treatment, from 5.3 to 10.5 per 100 person-years.
In plain wordsIn men with baseline cardiovascular disease, event rates appeared higher after degarelix treatment than before treatment.
Peptide
Degarelix
Outcome
IncreaseCardiovascular event rate with baseline cardiovascular disease
Study
n: not reported in source
Comparator
before treatment
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Measurements
Event rate before degarelix
5.3 events per 100 person-years
men with cardiovascular disease at baseline
Event rate after degarelix
10.5 events per 100 person-years
men with cardiovascular disease at baseline
Source sentences
Summary
In contrast, event rates appeared higher after degarelix treatment in men with cardiovascular disease at baseline (5.3 to 10.5 events per 100 person-years, p = 0.0013).
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408304
05HumanObservational studySafety outcome
In men with prostate cancer, degarelix dose was not independently associated with cardiovascular events.
In plain wordsIn men with prostate cancer, degarelix dose was not independently linked to cardiovascular events.
Peptide
Degarelix
Outcome
No significant changeCardiovascular event association with dose
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Source sentences
Summary
Degarelix dose and schedule were not independently associated with cardiovascular disease events.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408305
06HumanObservational studySafety outcome
In men with prostate cancer, degarelix schedule was not independently associated with cardiovascular events.
In plain wordsIn men with prostate cancer, degarelix schedule was not independently linked to cardiovascular events.
Peptide
Degarelix
Outcome
No significant changeCardiovascular event association with schedule
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1-month doses of 20 to 240 mg or 3-month doses of 240 to 480 mg · average 22 monthsAs given in this study (human).
Source sentences
Summary
Degarelix dose and schedule were not independently associated with cardiovascular disease events.
3 context sentences(design, population, supporting numbers)
Summary · context
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.
Summary · context
Data on 1,704 men who participated in a total of 9 clinical trials were pooled for analysis.
Summary · context
Patients received treatment with 1-month (20 to 240 mg) or 3-month (240 to 480 mg) doses of degarelix for an average of 22 months.
Report a problemFND-2194408306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.